At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,882 enrolled
Drug / intervention
Galantaminedrug
Likely dose
Galantamine 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational, Multi-Center Study to Demonstrate That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease
In Brief
An observational study evaluating Galantamine for Alzheimer's Disease. Completed, enrolled 1,882 participants.
Detailed Summary
The purpose of this study is to demonstrate that the change of attention measure is correlated with the changes of caregiver's burden after treatment with galantamine.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
Primary CompletionJan 2008
First PostedNov 2012
TodayJul 2026
First PostedNov 27, 2012
Enrollment StartMar 1, 2007
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.6 years ago
Interventions
Galantaminedrug
This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.